Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340306 | 0.87 | FAAH (0.50) | MEN1GAAKMT2AFAAH | |
| SCHEMBL9980629 | 0.85 | KMT2A (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL25968310 | 0.85 | KMT2A (0.54) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL9355239 | 0.82 | TDP1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL30340179 | 0.81 | GLP1R (0.52) | MEN1GAAKMT2ACHRM1 | |
| SCHEMBL31494690 | 0.81 | KMT2A (0.55) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31601080 | 0.81 | MEN1 (0.57) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL7375698 | 0.80 | TDP1 (0.55) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL14028752 | 0.80 | MEN1 (0.50) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL29553052 | 0.79 | FAAH (0.52) | MEN1GAAKMT2AFAAHCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| EP-3052135-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | Universitetet I Oslo (NO) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | MEN1 2293/4885GAA 76/4885KMT2A 2140/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | MEN1 2293/4885GAA 76/4885KMT2A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.